Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 18/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693164 | 0.91 | KRAS (0.49) | KRASHDAC6USP30 | |
| SCHEMBL24558243 | 0.91 | KRAS (0.49) | KRASHDAC6USP30 | |
| SCHEMBL29693103 | 0.90 | KRAS (0.44) | KRAS | |
| SCHEMBL24558238 | 0.90 | KRAS (0.44) | KRAS | |
| SCHEMBL23513000 | 0.89 | KRAS (0.49) | KRASHDAC6 | |
| SCHEMBL29693116 | 0.89 | KRAS (0.44) | KRASHDAC6USP30 | |
| SCHEMBL24558209 | 0.89 | KRAS (0.44) | KRASHDAC6USP30 | |
| SCHEMBL23512570 | 0.89 | KRAS (0.49) | KRASHDAC6 | |
| SCHEMBL24558478 | 0.87 | KRAS (0.41) | KRAS | |
| SCHEMBL29693199 | 0.87 | KRAS (0.42) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | KRAS 89/4885HDAC6 797/4885USP30 4265/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KRAS 89/4885HDAC6 797/4885USP30 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.